Gubra AS (CHIX:GUBRAC) Research & Development: kr239 Mil (TTM As of Dec. 2025)


CHIX:GUBRAC Gubra AS CHIX:GUBRAC
73 GF Score
Price kr354.50
GF Value kr2,972.88
! 3 Warning Signs
View Full Analysis

What is Gubra AS Research & Development?

Gubra AS CHIX:GUBRAC 73 Research & Development is kr239 Mil as of Dec. 2025. GuruFocus rates CHIX:GUBRAC with a GF Score™ of 73/100 and a GF Value™ of kr2,972.88. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Gubra AS's Research & Development for the six months ended in Dec. 2025 was kr92 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was kr239 Mil.

Gubra AS  (CHIX:GUBRAc) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gubra AS Research & Development Related Terms

Gubra AS Research & Development Historical Data

* Premium members only.

The historical data trend for Gubra AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gubra AS Research & Development Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 27.06 56.84 89.23 112.99 238.85

Gubra AS Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 47.27 49.75 63.24 146.73 92.12
CHIX:GUBRAC
73GF Score
Gubra AS CHIX:GUBRAC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gubra AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr239 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr239 Mil mean?
Gubra AS (CHIX:GUBRAC) has a Research & Development of kr239 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Gubra AS and its competitors.
Is Gubra AS's Research & Development too high?
Gubra AS's current Research & Development is kr239 Mil. Overall, Gubra AS has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Research & Development compare to VRTX and REGN?
Gubra AS's Research & Development of kr239 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Gubra AS and its competitors. Gubra AS's current Research & Development is kr239 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Gubra AS (CHIX:GUBRAC) has a current Research & Development of kr239 Mil. The stock's GF Value™ is kr2,972.88, compared to a current price of kr354.50 — trading 88.1% below its estimated fair value. The current Research & Development is kr239 Mil. Gubra AS's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Gubra AS (CHIX:GUBRAC), the current Research & Development is kr239 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gubra AS (CHIX:GUBRAC) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued. The current stock price of kr354.50 is trading 88.1% below its estimated GF Value™ of kr2,972.88.

Key valuation signals for CHIX:GUBRAC:

  • Research & Development: kr239 Mil
  • GF Value™: kr2,972.88 vs. price of kr354.50 (88.1% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the CHIX:GUBRAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gubra AS Business Description

Other Exchanges GUBRA:DenmarkPI3:Germany
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
73GF Score

Get the complete analysis for CHIX:GUBRAC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr354.50
Price
kr2,972.88
GF Value